**Supplementary Table 10. Prediction results of each cancer type using 133 CpG markers measured by bsCUP-seq in 100 clinical samples.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Cancer type** | **No. of cases** | **Correct in top-rank** | **Correct in 2nd rank** | **Incorrect** |
| BLCA | 5 | 5 | 0 | 0 |
| BRCA | 10 | 9 | 0 | 1 (LUAD) |
| CESC | 6 | 4 | 2 (1 CRAD, 1 LUAD) | 0 |
| CHOL | 5 | 0 | 2 (1 CESC, 1 LUAD) | 3 (1 BLCA, 1 CRAD, 1 LUSC) |
| CRAD | 10 | 7 | 2 (1 CESC, 1 ESST) | 1 (ESST) |
| ESST | 9 | 6 | 1 (MESO) | 2 (1 CESC, 1 LUAD) |
| KIPAN | 12 | 11 | 0 | 1 (SKCM) |
| LIHC | 10 | 8 | 1 (CHOL) | 1 (CHOL) |
| LUAD | 4 | 2 | 0 | 2 (1 CESC, 1 ESST) |
| LUSC | 2 | 0 | 0 | 2 (1 CESC, 1 ESST) |
| MESO | 1 | 1 | 0 | 0 |
| OV | 7 | 3 (2 UCEC, 1 OV) | 2 (2 CESC) | 2 (1 BLCA, 1 CESC) |
| PAAD | 7 | 0 | 0 | 7 (2 ESST, 2 LUAD, 1 CESC, 1 CHOL, 1 SKCM) |
| PRAD | 1 | 1 | 0 | 0 |
| SKCM | 1 | 1 | 0 | 0 |
| THCA | 4 | 4 | 0 | 0 |
| UCEC | 6 | 5 | 0 | 1 (CESC) |
| Total | 100 | 67 (67%) | 9 (9%) | 24 (24%) |

\*bracket: top-ranked tumor of each sample. Abbreviations: BLCA: bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical and endocervical carcinoma; CHOL, cholangiocarcinoma; CRAD, colorectal adenocarcinoma; ESST, esophageal and gastric adenocarcinoma; KIPAN, kidney renal cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovary serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; SKCM, skin cutaneous melanoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma.